clinical trial · NCT06484868
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Amryt Pharma·phase4·recruiting·n = 12
Partial LipodystrophyMetreleptin
brief summary
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
started
Feb 8, 2024
primary completion
Feb 1, 2028
completion
Feb 1, 2028
last updated
Jul 3, 2025
official title
A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol